Literature DB >> 20445478

Video fluoroscopic analysis of the effects of three commonly-prescribed off-the-shelf orthoses on vertebral motion.

Andrew Utter1, Meredith L Anderson, Joseph G Cunniff, Kenton R Kaufman, Elena J Jelsing, Todd A Patrick, Dixon J Magnuson, Timothy P Maus, Michael J Yaszemski, Jeffery R Basford.   

Abstract

STUDY
DESIGN: Fluoroscopic assessment of the effects of commercially available spinal orthotics on lumbar vertebral motion as subjects performed flexion and extension maneuvers.
OBJECTIVE: To quantitate the effects of 3 commonly available, off-the-shelf, soft, and semirigid spinal orthoses on lumbar spinal motion. SUMMARY OF BACKGROUND DATA: Commercially available soft and semirigid orthoses are widely prescribed for patients with low back pain and, at times, following surgery. Despite this use, surprisingly little is known about the magnitude of their effects on lumbar vertebral motion.
METHODS: Ten subjects (6 men and 4 women) with an average age of 27.0 +/- 5.3 years, underwent videofluoroscopic imaging as they performed a full flexion/extension cycle. Assessments, during which the subjects were unbraced or wearing either a soft lumbrosacral orthosis (LSO), a semirigid LSO, or a semirigid thoracolumbrosacral orthosis (TLSO) were performed in random order. Images were obtained at a rate of 3.75 Hz and digitally processed to determine the sagittal rotation of the L3-L5 vertebral bodies.
RESULTS: Each of the braces produced a statistically significant reduction in overall lumbar motion during the flexion maneuver (P = 0.007) but none had a detectable effect during extension. Relative effectiveness varied by vertebral level. At the L3-L4 level, only the TLSO had a statistically significant effect on intervertebral flexion movement (32%, P = 0.003). At the L4-L5 level all the orthoses were effective (and statistically indistinguishable) in their ability to reduce intervertebral flexion movements ranging from 48% for the semirigid TLSO to about 15% to 20% for the 2 LSOs. No effects were noted for any of the orthoses at the L5-S1 level.
CONCLUSION: Commercially available soft and semirigid orthotics can have significant effects on lumbar vertebral body motion at the L3-L4 and L4-L5 levels.

Entities:  

Mesh:

Year:  2010        PMID: 20445478     DOI: 10.1097/BRS.0b013e3181c62fa1

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  6 in total

1.  Design and Pilot Evaluation of a Reconfigurable Spinal Exoskeleton.

Authors:  Alwyn P Johnson; Maja Gorsic; Yubi Regmi; Bradley S Davidson; Boyi Dai; Domen Novak
Journal:  Annu Int Conf IEEE Eng Med Biol Soc       Date:  2018-07

Review 2.  Role of rehabilitation medicine and physical agents in the treatment of cancer-associated pain.

Authors:  Andrea L Cheville; Jeffrey R Basford
Journal:  J Clin Oncol       Date:  2014-05-05       Impact factor: 44.544

3.  A randomized clinical trial comparing extensible and inextensible lumbosacral orthoses and standard care alone in the management of lower back pain.

Authors:  David C Morrisette; Jacek Cholewicki; Sarah Logan; Gretchen Seif; Stephanie McGowan
Journal:  Spine (Phila Pa 1976)       Date:  2014-10-01       Impact factor: 3.468

4.  A Pilot Study of Varying Thoracic and Abdominal Compression in a Reconfigurable Trunk Exoskeleton During Different Activities.

Authors:  Maja Gorsic; Yubi Regmi; Alwyn P Johnson; Boyi Dai; Domen Novak
Journal:  IEEE Trans Biomed Eng       Date:  2019-09-09       Impact factor: 4.538

5.  A RCT comparing lumbosacral orthosis to routine physical therapy on postural stability in patients with chronic low back pain.

Authors:  Fatemeh Azadinia; Ismail Ebrahimi-Takamjani; Mojtaba Kamyab; Mohamad Parnianpour; Morteza Asgari
Journal:  Med J Islam Repub Iran       Date:  2017-05-01

6.  Efficacy of lumbar orthoses after posterior lumbar interbody fusion-a prospective randomized study.

Authors:  Hiroyasu Fujiwara; Takahiro Makino; Kazuo Yonenobu; Yu Moriguchi; Takenori Oda; Takashi Kaito
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.